Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer

NCT00458237 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Everolimus
DRUG: Trastuzumab

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]
[object Object]